NZ198942A - Combinations containing an anticholinergic drug with an antacid or h 2 -receptor antagonist - Google Patents
Combinations containing an anticholinergic drug with an antacid or h 2 -receptor antagonistInfo
- Publication number
- NZ198942A NZ198942A NZ198942A NZ19894281A NZ198942A NZ 198942 A NZ198942 A NZ 198942A NZ 198942 A NZ198942 A NZ 198942A NZ 19894281 A NZ19894281 A NZ 19894281A NZ 198942 A NZ198942 A NZ 198942A
- Authority
- NZ
- New Zealand
- Prior art keywords
- scopolamine
- drug
- anticholinergic
- pharmaceutical combinations
- therapeutic system
- Prior art date
Links
- 239000000812 cholinergic antagonist Substances 0.000 title claims description 15
- 229940069428 antacid Drugs 0.000 title claims description 14
- 239000003159 antacid agent Substances 0.000 title claims description 14
- 230000001458 anti-acid effect Effects 0.000 title claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims description 4
- 239000003485 histamine H2 receptor antagonist Substances 0.000 title 1
- 229960002646 scopolamine Drugs 0.000 claims description 56
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 50
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 50
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 50
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 50
- 239000003814 drug Substances 0.000 claims description 47
- 229940079593 drug Drugs 0.000 claims description 46
- 230000001225 therapeutic effect Effects 0.000 claims description 31
- 230000002496 gastric effect Effects 0.000 claims description 22
- 230000028327 secretion Effects 0.000 claims description 18
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 14
- 229940044551 receptor antagonist Drugs 0.000 claims description 13
- 239000002464 receptor antagonist Substances 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 229930003347 Atropine Natural products 0.000 claims description 5
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 5
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 5
- 229960000396 atropine Drugs 0.000 claims description 5
- 230000002195 synergetic effect Effects 0.000 claims description 3
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 claims description 2
- 229960001081 benzatropine Drugs 0.000 claims description 2
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 2
- 229960003561 etybenzatropine Drugs 0.000 claims description 2
- PHTMLLGDZBZXMW-AERCQKQUSA-N etybenzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2CC)C(C=1C=CC=CC=1)C1=CC=CC=C1 PHTMLLGDZBZXMW-AERCQKQUSA-N 0.000 claims description 2
- 229960000857 homatropine Drugs 0.000 claims description 2
- 239000010410 layer Substances 0.000 description 17
- -1 alkali metal salts Chemical class 0.000 description 15
- 239000002585 base Substances 0.000 description 13
- 239000002480 mineral oil Substances 0.000 description 13
- 235000010446 mineral oil Nutrition 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 229920002367 Polyisobutene Polymers 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 208000008469 Peptic Ulcer Diseases 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 229960001380 cimetidine Drugs 0.000 description 5
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000011906 peptic ulcer disease Diseases 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 239000004821 Contact adhesive Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 230000009858 acid secretion Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 206010013781 dry mouth Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000012790 adhesive layer Substances 0.000 description 3
- 230000001120 cytoprotective effect Effects 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229960000697 propantheline Drugs 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020601 Hyperchlorhydria Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229940116335 lauramide Drugs 0.000 description 2
- ILRSCQWREDREME-UHFFFAOYSA-N lauric acid amide propyl betaine Natural products CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000807 solvent casting Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YDDXVAXDYKBWDX-UHFFFAOYSA-N 1-cyano-3-[2-[[2-(diaminomethylideneamino)-4-thiazolyl]methylthio]ethyl]-2-methylguanidine Chemical compound N#CNC(=NC)NCCSCC1=CSC(N=C(N)N)=N1 YDDXVAXDYKBWDX-UHFFFAOYSA-N 0.000 description 1
- 229910018134 Al-Mg Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229910018467 Al—Mg Inorganic materials 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- JTPUMZTWMWIVPA-UHFFFAOYSA-O Isopropamide Chemical compound C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 JTPUMZTWMWIVPA-UHFFFAOYSA-O 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FPBPLBWLMYGIQR-UHFFFAOYSA-N Metiamide Chemical compound CNC(=S)NCCSCC=1N=CNC=1C FPBPLBWLMYGIQR-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- DUDKAZCAISNGQN-UHFFFAOYSA-N Oxyphencyclimine Chemical compound CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 DUDKAZCAISNGQN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- HOOSGZJRQIVJSZ-NNBUQUNQSA-N clidinium Chemical compound C1([C@H]2CC[N@+](CC2)(C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HOOSGZJRQIVJSZ-NNBUQUNQSA-N 0.000 description 1
- 229960003154 clidinium Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960001737 isopropamide Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229950003251 metiamide Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 229960002369 oxyphencyclimine Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229960005258 poldine Drugs 0.000 description 1
- CQRKVVAGMJJJSR-UHFFFAOYSA-N poldine Chemical compound C[N+]1(C)CCCC1COC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 CQRKVVAGMJJJSR-UHFFFAOYSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000005094 subcutaneous system Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229950011533 tiotidine Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
New Zealand Paient Spedficaiion for Paient Number 1 98942 "*.© A WIMi iriHif iiv riority Data(s): YZ,: .));9}p; Complete Specification Filed: l.V.U-31; a« A&kAs&jfe® • • • V' !.?.•** .1 Publication Date: . -t39l P.O. Journal, Mo: ..... A. I, 1 98942 Patents Form No. 5 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION l/l £rorf(C)^>.
O^" Ccjv-Cornvc. U - C. hereby declare the invention, for which-t/we pray that a patent may be granted to me/us, and the method by which it is to be performed, to be particularly described in and by the following statement:- (followed by page 1 A.) - lA- 198942 4-1314VARC 759/+ Use of anticholinergic drugs The present invention relates to cxnibinations containing an anticholinergic drug in the form of a parenteral useable therapeutic system which releases this drug continuously for the treatment of hyperacidity and peptic ulcers.
It is known that anticholinergic drugs can be administered oraly to treat hyperacidity and peptic ulcer conditions. In the newest edition of the textbook "The Pharmacological Basis of Therapeutics" by L.S.
Goodman and A. Gilman (MacMillan Publ. Co. Inc., New York, 1980, 6th ed.), it is said that antimuscarinic drugs of the atropine or scopolamine type that block at cholinergic receptors influence gastric secretion. It is pointed out, however, that only relatively large doses are effective. According to this current teaching, daily doses bordering on the subtoxic limit are necessary to inhibit gastric secretion. For example, when using scopolamine, doses of 1 mg and more are necessary to inhibit gastric secrection in humans. Such large doses, however, almost always cause serious side effects, e.g. dry mouth, impaired vision, photophobia, tachycardia and difficulty in urination and urinary retention. In Gastroenterology ^8, 154-166 (1975), K.J. Ivey comes to the same conclusion after a study of 400 publications on the use of anticholinergic drugs for treating peptic ulcers. The side effects are so intolerable that many patients are unable to endure the treatment over a prolonged period of time.
Investigations made by M. Feldman et al. [N. Engl. J. Med. 297, 1427-1430 (1977)] cast doubt on the view generally held up to now that gastric secretion can only be inhibited by administering very large doses of a parasympatholytic drug. These authors have found that a small dose (15 mg) of propantheline inhibits gastric secretion induced by intake of food in patients suffering from duodenal ulcer 198942 to the same extent as a subtoxic dose of 48mg. It has also been found that this smaller dose of propantheline, administered in combination with an Hj-receptor antagonist, e.g. cimetidine, inhibited acid secretion to a greater degree than did both drugs singly. Owing to the uncertain efficacy even in relatively large doses, this concept has not found widespread use in general.
Surprisingly, it has now been found that the use of anticholinergic drugs in the form of parenteral useable therapeutic systems which release said drugs continuously, effectively inhibit gastric secretion while reducing or totally eliminating unwelcome side effects. Suitable therapeutic systems which make possible a continuous release can be transdermal or intradermal, subcutaneous or intramuscular.
The invention relates in particular to combinations containing synergistic gastric section inhibiting amounts of an anticholinergic drug in the form of a therapeutic system which can be applied transdermally in the presence of acid inhibiting medicaments, e.g. antacids and/or Hj-receptor antagonist.
More particularly, the invention relates to such combinations wherein the anticholinergic drug is of the atropine type in the form of a therapeutic system which can be applied transdermally, in the presence of acid inhibiting medicaments, e.g. antacids and/or Hj-receptor antagonists, for inhibiting gastric secretion.
Very particularly, scopolamine is used as the anticholinergic drug in the form of a transdermal therapeutic system, in the presence of antacids and/or Hj-receptor antagonists, for inhibiting gastric secretion.
Most particularly, scopolamine base is used as »fche-.. anticholinergic drug in the form of a transdermal therapeutic system for inhibiting gastric secretion. Mo?** f80£. 198942 Anticholinergic drugs, which are also termed parasympatholytic, antmuscarinic or cholinolytic drugs, belong to the class of neutropic or atropine-type spasmolytic drugs.
Anticholinergic drugs which are used, inter alia, for inhibiting gastric secretion using a therapeutic system which releases the drug continuously, are described by G. Erhardt and H. Ruschig, Arznei-mittel, Vol. 2, pp 75-79 (1972). However, particularly important drugs for inhibiting gastric secretion using a therapeutic system for releasing medication continuously, are those of the atropine type, e.g. atropine, homatropine, scopolamine, benzatropine and etybenzatropine and the therapeutically useful salts thereof. Other anticholinergic drugs of special importance which can be used are, e.g. oxyphencycli-mine, glycopyrrolate, poldine, propantheline, isopropamide, and clidinium and the therapeutically useful salts therof.
The antacids and/or ^-receptor-antagonists can be administered oraly, or the H^-receptor-antagonists can be administered in combination with the anticholinergic drugs.
As I^-receptor antagonists there may be used drugs which strongly inhibit histamine-induced gastric secretion. Examples of suitable I^-receptor antagonists are ranitidine, metiamide, burimamide, tiotidine and, in particular, cimetidine, and the therapeutically useful salts thereof.
Suitable antacids which can be administered as e.g. the preparations described by B. and H.H. Helwig in "Moderne Arzneimittel", 5th edition, pp. 656-665, 1980. In particular, it is possible to use metal salts, e.g. alkali metal salts, alkaline earth metal salts and also salts of metals of Group III of the Periodic Table. Examples of especially suitable salts are carbonates or bicarbonates of sodium, calcium or magnesium, or also aluminium silicate . Other complex double silicates which produce an aluminium hydroxide film by hydrolysis, e.g. sodium 198942 aluminium silicates, can also be used. As further gastric acid inhibiting agents pepstatine, and cytoprotective agents including various prostaglandins, such as PGE^, and 16,16-dimethyl PGE^ may be used. rhe above mentioned canbinations in the form of a parenteral useable therapeutic systems which can be used eg; transdermally or intradermally, subcutan-eously or intramuscularly, release continously a drug at a certain rate and over a specific period of time. These therapeutic systems can also be employed in the practise of this invention for the continuous release of mixtures of drugs.
The transdermal therapeutic systems control the release of drug on the surface of intact skin. The rate of release is substantially below the maximum adsorption capacity of the skin. The drug diffuses through the epidermis and enters the circulation via the capillaries.
Intradermal systems are applied directly beneath the epidermis and subcutaneous systems beneath the dermis, e.g. as implantate in accordance with US patent No. 3 625 214, and they release the drug, controlled by biodegradation, continuously into the circulation.
Systems employing biodegradable polymers which control a continuous release of drug, for example as described in British Patent No: 15020821, can also be applied intramuscularly.
Preferably, however, therapeutic systems are used which are able to release continously the drug transdermally.
Depending on the utility of the different suitable anticholinergic drugs, there may be employed as transdermal therapeutic systems, e.g. thostdescribed in US patents Nos. 3 598 122,,2 598 123. 3 797 494 and 4 060 084, but preferably the transdermal therapeutic iS«S42 system described in U.S. Patents Nos. 4 031 894 and 4 262 003. ■ Hcwever, the utility of this invention is not restricted to the transdermal therapeutic systems disclosed in these publications. The systan desceibed in U.S. Patent 4,031,894 is a ■ ;— therapeutic drug delivery system in the form of plaster-type substrate which releases an anticholinergic drug, e.g. scopolamine base, in the presence or absence of an H -receptor antagonist, transdermally, 1 2 firstly at an initial rate of 10 to 200 of skin, and thereby rapidly brings the concentration of drug in the plasma to a value at which it inhibits gastric secretion without the unpleasant side effects referred to previously, and then in an amount of 0.3 to 15 ^ig/hr, such that the content of drug in the plasma is kept approximately constant. In most instances the pulse will be in the range of 50 to .2 150 jig of an anticholinergic, e.g. scopolamine per cm of skin of being treated.
The concentration of scopolamine in the plasma can be related to the concentration of free scopolamine in the urine if the glomerular filtration rate of the subject is known, and it is convenient to express the quantity of scopolamine in the plasma in terms of a urinary excretion rate. An average urinary excretion rate of about 0.5 ^ig free scopolamine per hr was found to generally correspond to a therapeutic plasma level. However, it was also found that this rate is subject to about a +5 fold biological variation. Therefore, the rate ranges between about 0.1 to 2.5 jig per hr depending on the individual.
The purpose of the subtantially constant rate administration portion of the method is to supplement, if necessary, the pulse administration in delivering enough anticholinergic to reach the above-mentioned therapeutic level and to hold that level for as long as is necessary. It follows that the constant rate administration portion will proceed for as long as therapy is required. In this regard a total (including - 198942 the pulse) of 0.1 to 2.5 mg anticholinergic administered in accordance with the above-described dosage program will provide a therapeutic effect for about 3 hours to 7 days. It also follows that the level of constant rate administration may vary depending on the body weight (plasma volume) of the patient. In this regard, in most instances the rate will be in the range of 1 to 15 ^ig per hr for adults and 0.5 to 15 yg per hr for children (measured as the steady rate of drug adminstration, i.e., after the initial 2 hr pulse administration) .
The substrate can consist of a multi-layered laminate comprising the following four layer when viewed from above: a) a protective backing, b) a gel-like drug reservoir consisting of a mixture of mineral oil and polyisobutene and which is the source of the constant drug release, c) a semipermeable membrane which partly controls the constant rate of release, and d) a gel-like adhesive layer containing the drug in a mixture of mineral oil and polyisobutene and acting as the source of the initial dose, and also comprising adhesive materials with which the substrate is affixed to the skin.
For the covering layer a) it is preferred to use a laminate of polymer sheeting and a metal sheeting, e.g. aluminium foil. Exemplary polymers which may be used for this layer are polyethylene of high and low density, polypropylene, polyvinyl chloride and polyethylene terephtha-late.
The scopolamine base contained in the drug reservoir b) is homogeneously dispersed - partly dissolved and partly undissolved - in the gel-like mixture of mineral oil having a viscosity of about 10 to 100 cP at 25°C and a polyisobutene. These mixtures of mineral oil and polyisobutene are excellent adhesives and serve in addition to 198942 hold the plaster-type substrate together. The mineral oil is used e.g. as carrier for the scopolamine base, which has limited solubility in the mineral oil (c. 2 mg/hl). The relative amounts in the reservoir are chosen such that the mineral oil is substantially saturated with the base during the entire release period of the substrate.
The next layer of the laminate is a semipermeable (microporous) layer c), the pores of which are filled with the mineral oil described above, which layer controls the rate at which the scopolamine base is released to the skin. The rate of flow of scopolamine through the semipermeable layer and the area covered by the membrane must be chosen such that the scopolamine is delivered to the skin from the reservoir layer substantially at a constant rate in the range from 0.3 to 15 ^ig/hr, after the transdermal therapeutic system has been applied to the skin. The semipermeable membrane is made of polymeric materials through which the drug is able to penetrate by diffusion. Exemplary polymers which can be used for such membranes are polypropylene, polycarbonates, polyvinyl chloride, cellulose acetate, cellulose nitrate, polyacrylonitrate and organopolysiloxane rubber.
The adhesive layer d) of the laminate is composed substantially of the same constituents as the layer b) above, and it also contains the scopolamine base as drug and is responsible for the initial large dose at the commencement of treatment with the system. The plaster-type substrate is affixed to the skin with the aid of the strongly adhesive layer d) after the removable protective layer has been removed immediately before application.
The parenteral useable therapeutic systems described in this invention and which effect continuous release of anticholinergic drugs in the presence or absence of antacids and/or I^-receptor antagonist, can be employed for inhibiting gastric secretion in acute gastritis 198942 or for treating peptic ulcers in the stomach or duodenum without the occurrence of unpleasant parasympathological side effects, e.g. dry mouth, impaired vision, photophobia, tachycardia and difficulty in urination and urinary retention.
For gastric acid inhibiting purposes and especially anti-ulcer therapy comprising administering orally a ^-receptor antagonist, the dosage unit will contain from about 25 mg to 250 mg of the drug. Generally, the dosage form containing the antagonists will be administered orally from one to six times a day, and the daily dosage will be from about 25 mg to 1500 mg of the ^-receptor antagonists. For therapeutic use, the dosage form comprising a PGE£ will contain about 0.1 mg to 3 mg of the prostaglandin, and the daily dose generally will be from about 0.1 mg to 10 mg administered 1 to 3 times a day. For antacids, the dosage form will contain from about 25 mg to 500 mg of an antacid administered orally from 1 to 6 times a day. A representative dosage form for a I^Teceptor antagonist comprises 150 mg of cimetidine and 100 mg of lactose filled into a hard gelatine capsule, for a prostaglanding 1 mg of PGE2, 27 mg of sucrose, 25 mg of starch, 5 mg of talc and 2 mg of magnesium stearate compressed into a tablet, and for an antacid 300 mg of aluminium magnesium antacid and 15 mg of magnesium stearate compressed into a tablet.
When used in conjunction with transdermal administration, the dosage may gradually be decreased as the patient responds to the transdermal administration of scopolamine. The transdermal dosages of scopolamine found useful are in the range of 0.05 to 25 yg/hv when used in conjunction with oral or parenteral administration of another antiulcer agent.
Bandages for the transdermal use are prepared as follows: 198942 a) A solution of 29.2 parts molecular weight polyisobutene (sold under the designation Vistanex MML-100, 1,200,000 viscosity average molecular weight), 36.5 parts low molecular weight polyisobutene (sold under the designation Vistanex LM-MS, 35,000 viscosity average molecular weight), 58.4 parts mineral oil (10 cp at 25°C), 15,7 parts scopolamine base and 860.2 parts chloroform is solvent cast onto an approximately 65 micron thick backing film of aluminized polyethylene terephthalate (sold under the desigantion MEDPAR) to form a scopolamine base reservoir layer approximately 50 microns thick. A contact adhesive layer-strippable coating combination is similarly prepared by solvent casting onto a 200 micron thick siliconized, aluminized, polyethylene-backed polyethylene terephthalate film a solution of 31.8 parts of said high molecular weight polyisobutene, 39.8 parts of said low molecular weight polyisobutene, 63.6 parts of said mineral oil, 4.6 parts of scopolamine base and 860.2 parts chloroform. The resulting contact adhesive layer is approximately 50 microns thick.
The above-described backing-reservoir layer combination is then laminated to one face of a 25 micron thick microporous polypropylene membrane (sold under the designation Celgard 2400) saturated with said mineral oil and the above-described contact adhesive layer- strippable coating combination is laminated to the opposite face of 2 the membrane. One cm circular, disc-shaped bandanges are punch cut from the resulting 5-layer laminate. Each bandage is designed to 2 release an initial 150 yg/cm pulse of scopolamine followed by an 2 . essentially constant dosage of 3 to 3.5 ^ig/cm /hr. b) A solution of 22.3 parts of the high molecular veight polyisobutene described in Example 1, 28.0 parts of the low molecular weight polyisobutene described in Example 1, 44.9 parts mineral oil (66 cp at25°C), 12.8 parts scopolamine base, 8.8 parts dimethyl lauramide and 883.2 parts of chloroform is solvent cast onto the backing film described in a) to form a scopolamine base reservoxr layer 198942 approximately 50 microns thick. A contact adhesive layer-strippable coating combination is similarly prepared by solvent casting onto the siliconized polyethylene terephthalate film described in a) a solution of 23.5 parts of said high molecular weight polyisobutene, 29.5 parts of said low molecular weight polyisobutene, 47.6 parts mineral oil (66 cpat25°C), 7.8 parts scopolamine base, 9.0 parts dimethyl lauramide and 882.6 parts chloroform. The resulting contact layer is approximately 50 microns thick.
The above described backing-reservoir layer combination is then laminated to one face of a 25 micron thick microporous polypropylene membrane (sold under the designation Celgard 2400) adhesive layer- strippable coating combination is laminated to the opposite face of 2 the membrane. Four cm circular, disc-shaped bandages are punch cut from the resulting 5-layer laminate. Each bandage is designed to 2 release an initial 125 ^ig/cm pulse of scopolamine followed by an 2 essentiallly constant dosage of 2 ^ig/cm /hr. c) Bandages were made according to the procedure of a) except that: the strippable coating was 127 microns thick siliconized 2 polyethylene terephthalate film and the bandages were each 2.5 cm in area. In vitro tests of these bandages showed they released an initial pulse of approximately 200 pg in the first two hours of use and an average of approximately 10 ^jg/hr thereafter through 72 hrs.
The invention is illustrated in more detail by the following non-limitative Example, in which parts are by weight unless otherwise stated. ,19 8942 Example 1; Young, healthy test persons are given a physical examination and tested for somatic condition, haematology, blood chemistry and urine. In order not to falsify the results of the examination, the test persons may not taken any other medication for one week before and during the period of the examination. The normal manner of living may not be altered during the study and ecxesses of any kind are avoided. A transdermal therapeutic system as described herein under a) b) and c) above and in the description part for the delivery of scopolamine is applied behind the ear to 8 healthy volunteer test persons over a period of 48 hours. Before the start of the assay, and on the 2nd and 4th day of the actual study, the acid secretion (HC1 and volume) is measured basally by the method of Lindenschmid et al., Zschr. Gastroenterologie 17, 820-826 (1979).
The gastric secretion is collected at 10 minute intervals by continuous suction. The amount of hydrochloric acid secreted is determined by titration of a 5 ml sample against 0.1N aqueous sodium hydroxide.
Side effects on the test persons are entered daily on a 100 mm scale. Blood pressure, pulse, and diameter of the pupil are entered on day 0, 2 and 4 of the study.
The following table shows that acid secretion decreases substantially using scopolamine in the form of a transdermal therapeutic system. 198942 Table I Action of scopolamine in the form of a transdermal therapeutic system on basal gastric secretion time period of study HC1 (mval/-£> test-versus x + s prevalue before TTS-scopolamine use 53 + 13 on day 2 during TTS-scopolamine use 31 + 15 ** 2 days after TTS-scopolamine use 22 + 20 * 1) paired t-test; n = 8 test persons * = p <0.05 ** = p <0.01 Example 2: Bandages were fastened to the post-auricular skin of five adult male duodenal ulcer patients ranging in age from 21 to 40 years after removing the strippable coating layer. A study was conducted over a period of 48 hours using placebo and scopolamine containing bandages on alternate nights. The placebo bandage was the same as the scopolamine-containing bandage except that it contained no scopolamine.
At mid-day before each study commenced the left post-auricular area was cleaned and either a placebo or a scopolamine bandage was applied to the skin. One hour later a standard meal'was eaten. Four hours later the patients were intubated with a sump tube and one hour after that another standard meal was consumed. From then until the next morning no food, only water, was taken. Five hours after the last meal the stomach contents were aspirated and discarded. Gastric secretion was collected hourly by pump suction for the next nine hours. 198942 Five ml aliquots of each hourly collection were used for measurement of pH and titration wiht 0.1 N sodium hydroxide to pH 7.00 using an automatic titrator. pH electrodes were calibrated between each determination with standard buffers.
Results after testing for two consecutive nights were expressed in terms of mean hourly acid output in millimoles per hour and mean hourly hydrogen ion concentration in millimoles per liter. Wilcoxon1s signed rank test and students' t-test for paired samples were, used for statistical analysis.
The mean hourly acid output was found to decrease from a mean of 6.8 + 1.8 mmoL^hr on the placebo night to 1.7 + 0.4 mmol/hr when the scopolamine-containing bandage was used. The results were statistically significant (p 0.001).
The hydrogen ion concentration was unaffected (79.1 + 6.4 mmol/1 on placebo; 68.2 + 3.5 mmol/1 on scopolamine-containing bandage).
Four of the patients had a dry mouth after overnight scoplolamine administration. One of the patients had a dry mouth soon after application of the scopolamine-containing bandage to the skin. There were no other reported side effects.
Example 3: Scopolamine may be used according to this invention to supplement conventional peptic ulcer therapy employing histamine receptor antagonists, cytoprotective agents and traditional neutralizing antacids$ for example. Bandages according to a), b) or c) may be used in conduction with other anti-peptic ulcer treatments by applying such bandage e'ach day to the mastoidal area of a patient suffering from peptic ulcer while administering the conventional peptic ulcer therapy as shown in Table II. 198942 Table II Drug Histamine Receptor Antagonist Cimetidine Cyto-protective Agent pge2 Antacids Al-Mg Salts Dosage 1 g per day with meals for 6 weeks followed by reduction to 400 mg per day for maintenance. 3 mg PGE2 3 times a day with meals reduced to 2 mg, 3 times per day with meals after 1 week for maintenance. 250 mg 3 times a day with meals followed by 100 mg 3 times a day with meals after 1 week for maintenance.
Example 4: A transdermal therapeutic system bandage (TTS) designed 2 to release scopolamine at a constant rate of 4 jug/cm /hr and deliver 0.5 mg of scopolamine at a steady rate over 3 days was worn by the subjects of this example in the post-auricular area. Overnight acid output was measured during two consecutive nights in 6 male duodenal ulcer patients in remission (age range 21-40, average age 31.2 years) admitted to a special ward for 48 hr. At mid-day before each study the left post-auricular area was cleanded and placebo (first stud]), or scopolamine-loaded (second study) TTS applied to the skin. At 17.00 hr the subjects were intubated with a 10 G Salem Sump tube 198942 (Argyle Medical). Standard meals were eaten by the subjects on both study days at 1300 and 1800 hr. with only water allowed thereafter. Stomach contents were aspirated and discarded at 23jOO hr and gastric secretion was then collected in hourly samples until 0800 hr by pumb suction, aided when required by syringe aspirin. 5 ml aliquots of each hourly collection were used for measurement of pH and titration with 0.1 N NaOH to pH 7,000, using an automatic titrator (Radiometer, Copenhagen). pH electrodes were calibrated between each determination with standard buffers.
All subjects were questioned about unwanted effects on each morning. Results were expressed in terms of mean hourly acid output in mmol h and in mean hourly hydrogen ion [H+] concentrations in mmol 1 Wilcoxon's signed rank test and student's t-test for paired samples were used for statistical analysis.
Results Placebo TTS gastric aspirates were technically unsatisfactory in one subject and he was excluded from analysis. In the remaining five patients the mean hourly (23.00-08.00 hr) acid output decreased from -1 ' a mean of 6.8 + SEM 1.8 mmol hr on the placebo night to 1.7 + 0.4 mmol hr^" when scopolamine filled ^TTS was used. This 75 percent inhibition of acid secretion was significant (p 0.001).
All the subjects responded to scopolamine administered via the TTS. The [H^j concentration was unaffected (79.1 + 6.4 mmol 1 ^ on placebo, 68.2 + 3.5 mmol 1 ^ on scopolamine). Some patients do not respond to blockade and one of the patients in this study was a cimetidine non-responder. His overnight acid output was decreased by 88 percent with TTS-scopolamine. While acid output decreased, the pH was unaffected so that gastric bacterial colonisation should not be a problem. Gastric juice collections were remarkable by the absence of mucus, in contrast to the appearance of gastric juice collected during ^-histamine blockade. Cholinergic agents stimulate mucus - 16 - 198942 secrection in the human alimentary tract, so that this observation should be further evaluated if TTS-scopolamine is used for prolonged periods.
The results of this study indicate that transdermal delivery of scopolamine at the rate of 5 ^ig hr''" using the TTS significantly inhibits nocturnal acid secrection in patients with DU. The TTS-scopolamine delivered the drug at a steady rate over 72 hr.
Various modifications of the above-described methods will be apparent to persons skilled in the medical, chemical and/or pharmaceutical arts and may be made without departing from the scope of the invention which is limited only by the following claims wherein: 198942 17
Claims (7)
1. Pharmaceutical combinations containing synergistic gastric secretion inhibiting amounts of an anticholinergic drug in the form of a parenteral useable therapeutic system which releases said drug continuously, and an antacid or H^-receptor antagonist, for simultaneous, separate or sequential administration, the separate or sequential administration being in a manner such as to produce the synergistic effect.
2. Pharmaceutical combinations according to Claim 1, wherein the anticholinergic drug is used in the form of a therapeutic system which can be applied transdermally, or intradermally, subcutaneously or intramuscularly, which system releases the drug continuously.
3. Pharmaceutical combinations according to Claim 1, wherein an anticholinergic drug is used in the form of a transdermal therapeutic system which releases said drug continuously.
4. Pharmaceutical combinations according to any preceding claim, wherein the anticholinergic drug is atropine, homatropine, scopolamine, benzatropine or etybenzatropine.
5. Pharmaceutical combinations according to any preceding claim, wherein scopolamine is used as anticholinergic drug in form of a transdermal therapeutic system, which releases scopolamine continuously in an amount of 0.3 to 15 ug/hr.
6. Pharmaceutical combinations according to Claim 1, wherein •< scopolamine is used as anticholinergic/drug in form of a transdermal therapeutic system, which releases scopolamine in an 2 initial pulse, of 10 to 200 ug/cm of skin and thereafter continuously in an amount of 0.3 to 1^ «rr/>n» - -
7. Pharmaceutical combinations as cla substantially as herein described, g
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH839180 | 1980-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ198942A true NZ198942A (en) | 1991-04-26 |
Family
ID=4339605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ198942A NZ198942A (en) | 1980-11-12 | 1981-11-11 | Combinations containing an anticholinergic drug with an antacid or h 2 -receptor antagonist |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0052074B1 (en) |
JP (1) | JPS57114508A (en) |
BE (1) | BE891069A (en) |
CY (1) | CY1457A (en) |
DE (2) | DE3175894D1 (en) |
GB (1) | GB2087234B (en) |
HK (1) | HK4889A (en) |
IT (1) | IT1172052B (en) |
MY (1) | MY8700681A (en) |
NL (1) | NL8104929A (en) |
NZ (1) | NZ198942A (en) |
PH (1) | PH19066A (en) |
ZA (1) | ZA817796B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2105990B (en) * | 1981-08-27 | 1985-06-19 | Nitto Electric Ind Co | Adhesive skin patches |
IL72684A (en) * | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
NZ213753A (en) * | 1984-10-11 | 1988-09-29 | Key Pharma | Transdermal delivery system containing anticholinergic reagent |
US4707495A (en) * | 1985-10-28 | 1987-11-17 | Ortho Pharmaceutical | Peptic ulcer treatment method |
WO1996008270A2 (en) * | 1994-09-13 | 1996-03-21 | Magainin Pharmaceuticals Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
US5714162A (en) * | 1994-09-16 | 1998-02-03 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Scopolamine patch |
JP2001267000A (en) | 2000-03-21 | 2001-09-28 | Sumitomo Wiring Syst Ltd | Water-proofconnector |
JO3510B1 (en) * | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | Use of glycopyrrolate for treating tachycardia |
JP6073231B2 (en) * | 2011-08-31 | 2017-02-01 | 興和株式会社 | Stable pharmaceutical composition |
JP2017014292A (en) * | 2016-10-24 | 2017-01-19 | ロート製薬株式会社 | Pharmaceutical composition |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4262003A (en) * | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
-
1981
- 1981-10-30 NL NL8104929A patent/NL8104929A/en not_active Application Discontinuation
- 1981-11-06 PH PH26453A patent/PH19066A/en unknown
- 1981-11-06 EP EP81810442A patent/EP0052074B1/en not_active Expired
- 1981-11-06 DE DE8181810442T patent/DE3175894D1/en not_active Expired
- 1981-11-09 DE DE19813144504 patent/DE3144504A1/en not_active Withdrawn
- 1981-11-10 BE BE0/206504A patent/BE891069A/en not_active IP Right Cessation
- 1981-11-10 GB GB8133811A patent/GB2087234B/en not_active Expired
- 1981-11-10 IT IT49667/81A patent/IT1172052B/en active
- 1981-11-11 JP JP56179885A patent/JPS57114508A/en active Granted
- 1981-11-11 ZA ZA817796A patent/ZA817796B/en unknown
- 1981-11-11 NZ NZ198942A patent/NZ198942A/en unknown
-
1987
- 1987-12-30 MY MY681/87A patent/MY8700681A/en unknown
-
1989
- 1989-01-19 HK HK48/89A patent/HK4889A/en unknown
- 1989-07-21 CY CY1457A patent/CY1457A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MY8700681A (en) | 1987-12-31 |
EP0052074A3 (en) | 1983-04-13 |
JPS57114508A (en) | 1982-07-16 |
IT8149667A0 (en) | 1981-11-10 |
DE3144504A1 (en) | 1982-06-24 |
BE891069A (en) | 1982-05-10 |
EP0052074B1 (en) | 1987-02-04 |
NL8104929A (en) | 1982-06-01 |
GB2087234A (en) | 1982-05-26 |
HK4889A (en) | 1989-01-27 |
DE3175894D1 (en) | 1987-03-12 |
ZA817796B (en) | 1982-10-27 |
GB2087234B (en) | 1986-06-25 |
JPH0150683B2 (en) | 1989-10-31 |
EP0052074A2 (en) | 1982-05-19 |
CY1457A (en) | 1989-07-21 |
PH19066A (en) | 1985-12-17 |
IT1172052B (en) | 1987-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK175375B1 (en) | Laminated composite for transdermal administration of fentanyl | |
RU2428186C2 (en) | Medical composition for percutaneous absorbtion, product keeping medical composition, and preparation for percutaneous absorbtion containing it | |
EP0498468B1 (en) | Device for transcutaneous application of nicotine | |
US5613958A (en) | Transdermal delivery systems for the modulated administration of drugs | |
US5635204A (en) | Method for transdermal induction of anesthesia, analgesia or sedation | |
RU2450805C2 (en) | Transdermal therapeutic system | |
US5186939A (en) | Laminated composite for transdermal administration of fentanyl | |
JP5856573B2 (en) | Transdermal delivery system | |
KR100267442B1 (en) | Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis | |
US4650484A (en) | Method for treating ischemic conditions | |
EP0431519A1 (en) | System for transdermal albuterol administration | |
WO2001008681A1 (en) | Methods of administration of glycopyrrolate compositions | |
WO2008021113A2 (en) | Transdermal methods and systems for treating alzheimer's disease | |
KR101891186B1 (en) | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions | |
Arndts et al. | Pharmacokinetics and pharmacodynamics of transdermally administered clonidine | |
JP2007238636A (en) | Novel formulation for transdermal delivery of pergolide | |
KR20000075648A (en) | Sustained analgesia achieved with buprenorphine | |
PT100502A (en) | PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE CAPACITY OF PERMEACAO IN THE SKIN USING GLYCEROL MONOLINOLEATE | |
AU2008268465A1 (en) | Transdermal delivery system comprising glycopyrrolate to treat sialorrhea | |
NZ198942A (en) | Combinations containing an anticholinergic drug with an antacid or h 2 -receptor antagonist | |
CA1309661C (en) | Transdermal delivery system | |
WO1997034587A2 (en) | Transdermal device | |
EP1652523A1 (en) | Transdermal absorption preparation | |
JP3571511B2 (en) | Transdermal formulation | |
KR100192149B1 (en) | Transdermal administration preparation of a 9-aminocyclopenta (b) quinoline |